Close Menu

Grants

Additional funding opportunities

Research Funding Opportunities

Tools to Find Funding

Grants Awarded for Health Sciences Research

Title Type $ Amount Activity Investigator Unitsort descending Sponsor Date
Web-based Physical Activity Intervention for Children with ALL Grant $175,000.00 Clinical Trial Holly Pariury Cancer Center Division Children's Hospital of Philadelphia 09/2020
Expanded Access Program Basis for the Treatment of Relapsed/Refractory Multiple Myeloma Contract $95,540.64 Clinical Trial Krisstina Gowin Cancer Center Division Glaxosmithkline 06/2020
A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic... Contract $297,912.00 Clinical Trial Rachna Shroff Cancer Center Division Covance, Incorporated 05/2020
Regulation of Intestinal Inflammation and Colon Cancer Development by AIM2 Grant $49,553.00 Research Justin Wilson Cancer Center Division Phi Beta Psi Sorority 07/2020
A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma (TRYbeCA-1 - TRial of ErYaspase Contract $664,687.53 Clinical Trial Hani Babiker Cancer Center Division PPD Investigator Services, LLC. 05/2020
Regulation of P-Body Formation and mRNA Decapping in Cancer: Control by AKT and Pim Kinase Phosphorylation of EDC3 Grant $394,690.00 Research Andrew Kraft Cancer Center Division National Cancer Institute 07/2020
A Three-Arm Study of ME-401 Monotherapy in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL), of ME-401 in Combination... Contract $298,700.00 Clinical Trial Daniel Persky Cancer Center Division Clinipace Worldwide 07/2020
Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-Type, Left-Sided Colorectal Cancer Contract $127,173.74 Clinical Trial Aaron Scott Cancer Center Division Academic Gastrointestinal Cancer Consortium 03/2020
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma Contract $258,643.47 Clinical Trial Jared Robbins Cancer Center Division Regeneron Pharmaceuticals, Inc 02/2020
Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY) Contract $159,936.00 Clinical Trial Pavani Chalasani Cancer Center Division IQVIA RDS Inc. 02/2020
Phase 1 Study of VE800 and Nivolumab in Patients with Selected Types of Advanced or Metastatic Cancer Contract $323,394.75 Clinical Trial Hani Babiker Cancer Center Division Vedanta Biosciences, Inc. 05/2020
Elecestrant Monotherapy VS. Standard Of Care For The Treatment Of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, OPEN-LABEL, Active-Controlled Contract $369,650.07 Clinical Trial Pavani Chalasani Cancer Center Division Radius Health, Inc. 02/2020
Phase 1/1b Multicenter, Open-Label, First-in-Human Dose Escalation and Dose Expansion Study to Assess Safety and Tolerability of Orally Administered PMD-026 in Patients with Metastatic Breast Cancer w Contract $100,897.00 Clinical Trial Pavani Chalasani Cancer Center Division Phoenix Molecular Designs (Canada) 02/2020
SWOG NCORP Research Base Cooperative Agreement $54,000.00 Clinical Trial Daniel Persky Cancer Center Division Oregon Health and Science University 07/2020
Noncoding RNA Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer Cooperative Agreement $64,679.91 Research Denise Roe Cancer Center Division Beckman Research Institute of The City of Hope 03/2020
A Phase 1 Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Contract $91,617.50 Clinical Trial Pavani Chalasani Cancer Center Division Zeno Pharmaceuticals, Inc. 01/2020
A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection in Patients with Advanced/Metastatic Solid Tumors Contract $458,027.74 Clinical Trial Hani Babiker Cancer Center Division Parexel International Corporation 01/2020
Aberrant DNA Repair and Lupus Grant $6,175,318.00 Research Joann Sweasy Cancer Center Division National Institute of Environmental Health Sciences 07/2020
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Efficacy and Safety of Anamorelin HCL for the Treatment OF Malignancy Associated Weight Loss and Anorexia... Contract $42,626.00 Clinical Trial Charles Hsu Cancer Center Division PSI Pharma Support America, Incorporated 01/2020
Structure and Function of DNA Repair Enzymes and Cancer Grant $487,283.00 Research Joann Sweasy Cancer Center Division University of Vermont 03/2020
A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors Contract $513,891.00 Clinical Trial Montaser Shaheen Cancer Center Division Ascentage Pharma 01/2020
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA Non-Mutated Advanced... Contract $100,897.00 Clinical Trial Setsuko Chambers Cancer Center Division GOG Foundation, Inc. 08/2020
The Role of an MSH6 Gene Variant and UV Radiation in Systemic Lupus Erythematosus Grant $174,926.00 Research Rithy Meas Cancer Center Division National Institute of Environmental Health Sciences 08/2020
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel.. Contract $327,830.00 Clinical Trial Abhijeet Kumar Cancer Center Division Covance, Incorporated 01/2020
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors Contract $682,977.50 Clinical Trial Edward Gelmann Cancer Center Division Pharmacyclics Incorporated 04/2020

Pages